LUSAKA, Feb. 10 (Xinhua) -- Zambia's medicines regulator on Wednesday said it intends to embark on studies aimed at exploring the efficacy of Ivermectin for the treatment and prevention of COVID-19.
The Zambia Medicines Regulatory Authority (ZAMRA) said it has been monitoring the use of the drug for the treatment and prevention of COVID-19 in other countries.
"The Zambia Medicines Regulatory Authority wishes to inform members of the public that the authority has continued monitoring developments regarding use of Ivermectin for the treatment and prevention of COVID-19. ZAMRA has noted the position adopted by some countries within the region to allow for use of Ivermectin for prevention and treatment of COVID-19 on compassionate grounds in a controlled-access program under supervision," said Christabel IIiamupu, the regulator's spokesperson, in a release.
While saying the drug will only be used in approved clinical trials where participants will be closely monitored and generated evidence will inform policy on the prevention or treatment of COVID-19, the spokesperson stressed ZAMRA would continue to support researchers who intend to investigate possible treatment or prevention of the disease by expediting the process of the applications for conduct of clinical trials. Enditem
